Raltegravir/Kaletra Combination Does Well (July 21, 2010)
A "nuke-sparing" combination of the integrase inhibitor raltegravir (Isentress) and the protease inhibitor drug lopinavir/ritonavir (Kaletra) looks highly promising, according to research presented to the conference.
From aidsmap.com On TheBodyPRO.com
Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.